- News Home
10 April 2014 11:44 am ,
Vol. 344 ,
The Pyrenean ibex, an impressive mountain goat that lived in the central Pyrenees in Spain, went extinct in 2000. But a...
Tight budgets are forcing NASA to consider turning off one or more planetary science projects that have completed their...
Ebola is not a stranger to West Africa—an outbreak in the 1990s killed chimpanzees and sickened one researcher. But the...
In an as-yet-unpublished report, an international panel of geoscientists has concluded that a pair of deadly...
Tropical disease experts tried and failed before to eradicate yaws, a rare disfiguring disease of poor countries. Now,...
Since 2002, researchers have reported that agricultural communities in the hot and humid Pacific Coast of Central...
Balkan endemic kidney disease surfaced in the 1950s and for decades defied attempts to finger the cause. It occurred...
- 10 April 2014 11:44 am , Vol. 344 , #6180
- About Us
Two-For-One Special on Diseases
31 January 2006 (All day)
STOCKHOLM--Public health efforts in the developing world are missing out on a bargain, say a group of researchers and health policy leaders. They argue that the ramped-up efforts against the Big Three--HIV/AIDS, tuberculosis, and malaria--will yield far bigger dividends if they are coupled with an attack on so-called neglected diseases such as hookworm, schistosomiasis, and leishmaniasis. Those parasites make their victims more susceptible to the Big Three, say scientists, who add that fighting both categories requires a similar public health infrastructure.
Maladies such as lymphatic filariasis and onchocerciasis take their toll through stunted growth, anemia, and blindness, contributing to widespread developmental and learning delays. Such forgotten infections "are the world's leading cause of growth deficits," yet they would be relatively cheap to treat, says Peter Hotez, a parasitologist at George Washington University in Washington, D.C. In a paper published 30 January in the Public Library of Science Medicine, Hotez and his colleagues argue that treating the 500 million people afflicted with one or more of these neglected diseases would cost just 40 cents per person per year, compared to more than $20 per person per year for fighting malaria. "It's the best buy in public health at the moment," says Alan Fenwick, a schistosomiasis researcher at Imperial College London and an author on the paper.
At the same time, the authors argue, such treatments might boost the ongoing fight against the Big Three. They point to a growing body of evidence that suggests that populations infected with multiple parasites are more susceptible to other diseases--including the big killers. For example, Hotez points to a study in Senegal that found that deworming medicines reduced malaria cases by 90%. And distribution systems for deworming drugs can also distribute antimalarial bed nets, he says.
The team hopes to put its ideas into practice soon. At a meeting here yesterday and today sponsored by the U.N. Millennium Project--an advisory body that aims to reduce poverty, hunger, and disease worldwide--researchers, representatives of donor organizations, pharmaceutical companies, and public health leaders from eight African countries met to devise a "quick impact initiative" that would create national programs to tackle malaria and the neglected diseases together.
Getting drugs where they are most needed is the greatest challenge, says William Lin of Johnson & Johnson. Lin is in charge of his company's effort to donate 50 million doses of mebendazole, used to treat hookworm and other helminths. "I've asked them to ramp up production," he says. "I don't want to be left at the end of the year with stores in the warehouse--and egg on my face."